DFX Intelligence

Data Factory

VentureFirmmulti stage vc · probableregistered_investment_adviser

Vivo Capital, LLC

Venture Capital

Palo Alto, CA

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:39bca202-32a1-44cb-b829-9e560196a846

Data as of Sep 16, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 7:35 PM UTC and rebuilt at most every 15 minutes.

Relationships: 145
Dated events: 40
On other graphs: 4
Observed: Sep 12, 2026 to Sep 16, 2026
60 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Independent Sponsorsidentity

Vivo Capital, LLC

Capital provider to sponsors · cited, shared crd

Private Equityidentity

Vivo Capital, LLC

Private equity manager · cited, shared crd

RIA / Wealth Managementidentity

VIVO CAPITAL, LLC

Registered adviser · cited, shared crd

Allocatorsidentity

Vivo Capital, LLC

Manager with allocator commitments · cited, shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 29
Vintages: 2011 to 2024
Reported GAV: $6.0Bgross asset value on Form ADV; never dry powder
Regulatory AUM: $6.1B
Funds with fundraising evidence: 0derived
Investments: 78
Portfolio companies: 75
Investments, 12m: 78
Partner-attributed: 0
People: 31
Investment professionals: 25derived
Co-investors: 0derived
LP relationships: 4
Stated sectors: healthcare,biotechas stated by the firm
Stated geography: global
Latest Form D: Jan 20, 2026
Latest ADV filing: Mar 31, 2026
Website: vivocapital.com

Funds

Fund	Vintage	Lifecycle	Form D sold	GAV	LPs
Vivo Co-Invest (c), L.P.	2024	Early deployment	$0	$150M	0
Vivo Innovation Fund II Holdings, L.P	2023	Active deployment	$0	$340M	0
Vivo Capital Fund X, L.P.	2023	Fundraising	$717M	$548M	0
Vivo Asia Opportunity Fund Holdings, L.P.	2023	Active deployment	n/a	$118M	0
Vivo Opportunity Fund Holdings, L.P.	2023	Active deployment	n/a	$1.0B	0
Vivo Co-Invest (s), L.P.	2023	Active deployment	$0	$50.0M	0
Vivo Asia Opportunity Fund, L.P.	2022	Wound down	n/a	$105M	0
Vivo Innovation Fund II, L.P.	2021	Wound down	n/a	$209M	0
Vivo Opportunity Co-Invest (w), L.P.	2020	Wound down	n/a	$17.1M	0
Vivo Opportunity Co-Invest, L.P.	2020	Mature	n/a	$81.5M	0
Vivo Super Viii Limited	2019	Mature	n/a	$225M	0
Vivo Opportunity Fund, L.P.	2018	Wound down	n/a	$656M	1
Vivo Capital Fund Ix, L.P.	2018	Harvest	$1.4B	$2.6B	1
Vivo Panda Fund, LP	2016	Harvest	$100M	$74.7M	0
Vivo Capital Surplus Fund Viii, L.P.	2015	Harvest	n/a	$84.1M	1
Vivo Capital Fund Viii, L.P.	2014	Harvest	$601M	$609M	1
Vivo Ventures VII Affiliates Fund, LP	2011	Harvest	$6.4M	$1.2M	0
Biotechnology Development Fund, LP	n/a	Wound down	n/a	$471,763	0
Biotechnology Development Fund IV Affiliates, LP	n/a	Wound down	n/a	$127,612	0
Bioasia Crossover Fund, LP	n/a	Wound down	n/a	$0	0
Vivo Ventures V Affiliates Fund, LP	n/a	Wound down	n/a	$36,607	0
Biotechnology Development Fund II, LP	n/a	Wound down	n/a	$2.3M	0
BDF IV Annex Fund, LP	n/a	Wound down	n/a	$244,252	0
Vivo Ventures Fund VI, LP	n/a	Wound down	n/a	$4.8M	0
Vivo Ventures VI Affiliates Fund, LP	n/a	Wound down	n/a	$100,074	0

Investments

round size is never this investor's check

Company	State	Stage	Round size	Partner	Attribution	Observed
HCMed Innovations	n/a	n/a	n/a	n/a	Unknown	Sep 19, 2026
Ascendispharma	n/a	n/a	n/a	n/a	Unknown	Sep 18, 2026
Ajax Therapeutics, Inc.	NY	n/a	n/a	n/a	Unknown	Sep 16, 2026
Agno Pharma	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
BioDlink	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
AkiraBio	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Ascendispharma	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Cidara Therapeutics, Inc.	CA	n/a	n/a	n/a	Unknown	Sep 16, 2026
Avadel Pharmaceuticals	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Avistone Pharmaceuticals	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Esco Lifesciences Group	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
BlossomHill Therapeutics, Inc.	CA	n/a	n/a	n/a	Unknown	Sep 16, 2026
Bolt Biotherapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Bonraybio	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Caidya	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Altoneuroscience	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Compass Pathways	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Compass Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Createrna Science and Technology	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Dominique Dutscher	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
EpiBiologics, Inc.	CA	n/a	n/a	n/a	Unknown	Sep 16, 2026
Esco Aster	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Achieve Life Sciences	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Evaheart Medical Device	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Aadi	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026

Co-investors

pairs come only from shared rounds and listings

Investor	Co-investor	Shared deals	Shared companies	Last observed	Strength
Vivo Capital, LLC	Avoro Capital Advisors LLC	5	5	Sep 18, 2026	Strong
Vivo Capital, LLC	Decheng Capital LLC	2	2	Sep 16, 2026	Recurring
Vivo Capital, LLC	RA Capital Management, LP	2	2	Sep 16, 2026	Recurring
Vivo Capital, LLC	Addition, L.P.	1	1	Sep 18, 2026	One time
Sofinnova Investments, Inc.	Vivo Capital, LLC	1	1	Sep 18, 2026	One time
Vivo Capital, LLC	Avego Management, LLC	1	1	Sep 16, 2026	One time
Vivo Capital, LLC	Mission Biocapital	1	1	Sep 16, 2026	One time
Vivo Capital, LLC	Arch Venture Partners	1	1	Sep 16, 2026	One time
Longitude Capital Management Co., LLC	Vivo Capital, LLC	1	1	Sep 16, 2026	One time
Adjuvant Capital, LP	Vivo Capital, LLC	1	1	Sep 16, 2026	One time
Vivo Capital, LLC	Omega Fund Management, LLC	1	1	Sep 16, 2026	One time
Vivo Capital, LLC	Windham Venture Partners	1	1	Sep 16, 2026	One time
Vivo Capital, LLC	Spruce Capital Partners	1	1	Sep 16, 2026	One time
Vivo Capital, LLC	Vida Ventures	1	1	Sep 16, 2026	One time
Vivo Capital, LLC	Qiming	1	1	Sep 16, 2026	One time

Relationships

showing 80 of 145

Invested in (75)

→ HCMed InnovationsCompanyPortfolio listing
Sep 19, 2026 to presentfactThe subject's own site
→ AscendispharmaCompanyPortfolio listing
Sep 18, 2026 to presentfactThe subject's own site
→ 再鼎医药CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ WuXi PharmaTechCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Visirna TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Visen PharmaceuticalsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Verona PharmaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Tranquis TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Tenax Therapeutics, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Zenas BioPharma, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ New Frontier CorporationCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Oricell TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Ossium HealthCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Pasithea TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Precision BioSciencesCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Provivi, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ PulmocideCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ RareStone GroupCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ RayzebioCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ RemeGenCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Ronovo SurgicalCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Sanegene BioCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Scientia VascularCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Sera PrognosticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Seran BioscienceCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Serapha BioCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Sierra OncologyCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Silence TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Sinovac BiotechCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Sinovac Life & SciencesCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
and 45 more

Employs (3)

→ Edgar G. EnglemanPersonManaging Partner
factThe subject's own site
→ Gaurav AggarwalPersonManaging Partner
factThe subject's own site
→ Michael ChanPersonAnalyst
factThe subject's own site

Dated events

30 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Mar 28, 2024
Person left
Hongbo (nmn) Lu (Managing Partner) no longer on Schedule A of Vivo Capital, LLC
Form ADVobserved 7 days ago
Occurred
Jan 1, 2021
Person joined
Jack Bech Nielsen joined Schedule A of Vivo Capital, LLC as Managing Partner
Form ADVobserved 7 days ago
Occurred
Jan 1, 2021
Person joined
Michael J. Chang joined Schedule A of Vivo Capital, LLC as Managing Partner
Form ADVobserved 7 days ago
Occurred
Jan 1, 2021
Person joined
Hongbo (nmn) Lu joined Schedule A of Vivo Capital, LLC as Managing Partner
Form ADVobserved 7 days ago
Occurred
Sep 9, 2020
Person left
Albert (nmn) Cha (Managing Partner) no longer on Schedule A of Vivo Capital, LLC
Form ADVobserved 7 days ago
Occurred
Aug 31, 2020
Person left
Chen Ming Yu (Managing Partner) no longer on Schedule A of Vivo Capital, LLC
Form ADVobserved 7 days ago
Occurred
Nov 1, 2019
Person joined
Zhanping (nmn) Wu joined Schedule A of Vivo Capital, LLC as General Counsel / Chief Compliance Officer
Form ADVobserved 7 days ago
Occurred
Jan 1, 2015
Person joined
Shan No Middle Name Fu joined Schedule A of Vivo Capital, LLC as Managing Partner
Form ADVobserved 7 days ago
Occurred
Jan 1, 2015
Person joined
Chen Ming Yu joined Schedule A of Vivo Capital, LLC as Managing Partner
Form ADVobserved 7 days ago
Occurred
Mar 28, 2012
Adviser's first ADV filing
Vivo Ventures, LLC first filed Form ADV (ERA, venture capital fund adviser exemption)
Form ADVobserved 7 days ago

Show 30 bookkeeping events

Occurred
Mar 28, 2024
Vivo Ventures VI Affiliates Fund, LP no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 28, 2024
Vivo Co-Invest (c), L.P. first reported on Form ADV by Vivo Capital, LLC (Private Equity Fund), GAV $150,000,000
Occurred
Mar 28, 2024
Vivo Capital Fund X, L.P. first reported on Form ADV by Vivo Capital, LLC (Private Equity Fund), GAV $547,959,184
Occurred
Mar 28, 2024
Vivo Ventures Fund VI, LP no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 31, 2023
Vivo Opportunity Fund, L.P. no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 31, 2023
Vivo Innovation Fund II, L.P. no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 31, 2023
Vivo Ventures V Affiliates Fund, LP no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 31, 2023
Vivo Co-Invest (s), L.P. first reported on Form ADV by Vivo Capital, LLC (Venture Capital Fund), GAV $50,004,383
Occurred
Mar 31, 2023
Vivo Innovation Fund II Holdings, L.P first reported on Form ADV by Vivo Capital, LLC (Venture Capital Fund), GAV $362,688,310
Occurred
Mar 31, 2023
Vivo Opportunity Fund Holdings, L.P. first reported on Form ADV by Vivo Capital, LLC (Other Private Fund), GAV $661,397,218
Occurred
Mar 31, 2023
Vivo Asia Opportunity Fund Holdings, L.P. first reported on Form ADV by Vivo Capital, LLC (Other Private Fund), GAV $158,004,158
Occurred
Mar 31, 2023
Vivo Ventures Fund V, LP no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 31, 2023
Vivo Asia Opportunity Fund, L.P. no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 31, 2022
Vivo Opportunity Co-Invest (w), L.P. no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 31, 2022
Vivo Asia Opportunity Fund, L.P. first reported on Form ADV by Vivo Capital, LLC (Private Equity Fund), GAV $105,381,862
Occurred
Mar 31, 2021
Vivo Innovation Fund II, L.P. first reported on Form ADV by Vivo Capital, LLC (Venture Capital Fund)
Occurred
Mar 27, 2020
Vivo Opportunity Co-Invest, L.P. first reported on Form ADV by Vivo Capital, LLC (Private Equity Fund), GAV $94,766,777
Occurred
Mar 27, 2020
Vivo Opportunity Co-Invest (w), L.P. first reported on Form ADV by Vivo Capital, LLC (Private Equity Fund), GAV $23,700,528
Occurred
Mar 27, 2020
BDF IV Annex Fund, LP no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 27, 2020
Biotechnology Development Fund IV, LP no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 27, 2020
Biotechnology Development Fund II, LP no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 27, 2020
Biotechnology Development Fund IV Affiliates, LP no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Mar 29, 2019
Vivo Super Viii Limited first reported on Form ADV by Vivo Capital, LLC (Venture Capital Fund), GAV $162,559,245
Occurred
Mar 29, 2019
Vivo Capital Fund Ix, L.P. first reported on Form ADV by Vivo Capital, LLC (Venture Capital Fund), GAV $879,107,034
Occurred
Mar 30, 2018
Vivo Opportunity Fund, L.P. first reported on Form ADV by Vivo Capital, LLC (Venture Capital Fund), GAV $395,757,576
Occurred
Mar 30, 2018
Biotechnology Development Fund, LP no longer reported on Form ADV by Vivo Capital, LLC
Occurred
Jun 30, 2016
Vivo Panda Fund, LP first reported on Form ADV by Vivo Capital, LLC (Venture Capital Fund), GAV $100,306,122
Occurred
Mar 26, 2015
Vivo Capital Surplus Fund Viii, L.P. first reported on Form ADV by Vivo Ventures, LLC (Venture Capital Fund), GAV $30,612,245
Occurred
Mar 26, 2015
Vivo Capital Fund Viii, L.P. first reported on Form ADV by Vivo Ventures, LLC (Venture Capital Fund), GAV $405,765,306
Occurred
Mar 28, 2014
Bioasia Crossover Fund, LP no longer reported on Form ADV by Vivo Ventures, LLC

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 website (Form ADV) · as of 2026-09-12

Also named here, with no published line of their own (reach them through the firm): Edgar G. Engleman (Managing Partner), Gaurav Aggarwal (Managing Partner), Michael Chan (Analyst).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Venture Capital
Canonical id: dfx:vc:39bca202-32a1-44cb-b829-9e560196a846
First observed: Sep 12, 2026
Last observed: Sep 16, 2026 3 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
3 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Vivo Capital, LLC

Venture Capital

Palo Alto, CA

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:39bca202-32a1-44cb-b829-9e560196a846

Data as of Sep 16, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 7:35 PM UTC and rebuilt at most every 15 minutes.

Fund

Vintage

Lifecycle

Form D sold

GAV

LPs

Vivo Co-Invest (c), L.P.

2024

Early deployment

$150M

Vivo Innovation Fund II Holdings, L.P

2023

Active deployment

$340M

Vivo Capital Fund X, L.P.

2023

Fundraising

$717M

$548M

Vivo Asia Opportunity Fund Holdings, L.P.

2023

Active deployment

n/a

$118M

Vivo Opportunity Fund Holdings, L.P.

2023

Active deployment

n/a

$1.0B

Vivo Co-Invest (s), L.P.

2023

Active deployment

$50.0M

Vivo Asia Opportunity Fund, L.P.

2022

Wound down

n/a

$105M

Vivo Innovation Fund II, L.P.

2021

Wound down

n/a

$209M

Vivo Opportunity Co-Invest (w), L.P.

2020

Wound down

n/a

$17.1M

Vivo Opportunity Co-Invest, L.P.

2020

Mature

n/a

$81.5M

Vivo Super Viii Limited

2019

Mature

n/a

$225M

Vivo Opportunity Fund, L.P.

2018

Wound down

n/a

$656M

Vivo Capital Fund Ix, L.P.

2018

Harvest

$1.4B

$2.6B

Vivo Panda Fund, LP

2016

Harvest

$100M

$74.7M

Vivo Capital Surplus Fund Viii, L.P.

2015

Harvest

n/a

$84.1M

Vivo Capital Fund Viii, L.P.

2014

Harvest

$601M

$609M

Vivo Ventures VII Affiliates Fund, LP

2011

Harvest

$6.4M

$1.2M

Biotechnology Development Fund, LP

n/a

Wound down

n/a

$471,763

Biotechnology Development Fund IV Affiliates, LP

n/a

Wound down

n/a

$127,612

Bioasia Crossover Fund, LP

n/a

Wound down

n/a

Vivo Ventures V Affiliates Fund, LP

n/a

Wound down

n/a

$36,607

Biotechnology Development Fund II, LP

n/a

Wound down

n/a

$2.3M

BDF IV Annex Fund, LP

n/a

Wound down

n/a

$244,252

Vivo Ventures Fund VI, LP

n/a

Wound down

n/a

$4.8M

Vivo Ventures VI Affiliates Fund, LP

n/a

Wound down

n/a

$100,074

Company

State

Stage

Round size

Partner

Attribution

Observed

HCMed Innovations

n/a

Unknown

Sep 19, 2026

Ascendispharma

n/a

Unknown

Sep 18, 2026

Ajax Therapeutics, Inc.

n/a

Unknown

Sep 16, 2026

Agno Pharma

n/a

Unknown

Sep 16, 2026

BioDlink

n/a

Unknown

Sep 16, 2026

AkiraBio

n/a

Unknown

Sep 16, 2026

Ascendispharma

n/a

Unknown

Sep 16, 2026

Cidara Therapeutics, Inc.

n/a

Unknown

Sep 16, 2026

Avadel Pharmaceuticals

n/a

Unknown

Sep 16, 2026

Avistone Pharmaceuticals

n/a

Unknown

Sep 16, 2026

Esco Lifesciences Group

n/a

Unknown

Sep 16, 2026

BlossomHill Therapeutics, Inc.

n/a

Unknown

Sep 16, 2026

Bolt Biotherapeutics

n/a

Unknown

Sep 16, 2026

Bonraybio

n/a

Unknown

Sep 16, 2026

Caidya

n/a

Unknown

Sep 16, 2026

Altoneuroscience

n/a

Unknown

Sep 16, 2026

Compass Pathways

n/a

Unknown

Sep 16, 2026

Compass Therapeutics

n/a

Unknown

Sep 16, 2026

Createrna Science and Technology

n/a

Unknown

Sep 16, 2026

Dominique Dutscher

n/a

Unknown

Sep 16, 2026

EpiBiologics, Inc.

n/a

Unknown

Sep 16, 2026

Esco Aster

n/a

Unknown

Sep 16, 2026

Achieve Life Sciences

n/a

Unknown

Sep 16, 2026

Evaheart Medical Device

n/a

Unknown

Sep 16, 2026

Aadi

n/a

Unknown

Sep 16, 2026

Investor

Co-investor

Shared deals

Shared companies

Last observed

Strength

Vivo Capital, LLC

Avoro Capital Advisors LLC

Sep 18, 2026

Strong

Vivo Capital, LLC

Decheng Capital LLC

Sep 16, 2026

Recurring

Vivo Capital, LLC

RA Capital Management, LP

Sep 16, 2026

Recurring

Vivo Capital, LLC

Addition, L.P.

Sep 18, 2026

One time

Sofinnova Investments, Inc.

Vivo Capital, LLC

Sep 18, 2026

One time

Vivo Capital, LLC

Avego Management, LLC

Sep 16, 2026

One time

Vivo Capital, LLC

Mission Biocapital

Sep 16, 2026

One time

Vivo Capital, LLC

Arch Venture Partners

Sep 16, 2026

One time

Longitude Capital Management Co., LLC

Vivo Capital, LLC

Sep 16, 2026

One time

Adjuvant Capital, LP

Vivo Capital, LLC

Sep 16, 2026

One time

Vivo Capital, LLC

Omega Fund Management, LLC

Sep 16, 2026

One time

Vivo Capital, LLC

Windham Venture Partners

Sep 16, 2026

One time

Vivo Capital, LLC

Spruce Capital Partners

Sep 16, 2026

One time

Vivo Capital, LLC

Vida Ventures

Sep 16, 2026

One time

Vivo Capital, LLC

Qiming

Sep 16, 2026

One time